Resumen
Standard neoadjuvant chemotherapy, based on taxanes and anthracyclines, makes conservative treatment of breast cancer possible and it allows for the evaluation of the tumor response in terms of achieving pathological complete response. Whereas hypoxia participates in carcinogenesis, resulting in less differenced tumor cells and poorer prognosis, HIF-1a could be predictive of the tumor response to treatment. Nonetheless, very few studies have evaluated the predictive value of HIF-1a in breast cancer in patients receiving neoadjuvant chemotherapy.